Please wait a minute...
European Journal of Gynaecological Oncology  2021, Vol. 42 Issue (1): 139-147    DOI: 10.31083/j.ejgo.2021.01.2192
Original Research Previous articles | Next articles
Using HE4, RMI, ROMA and CPH-I in the differential diagnosis of adnexal masses
Zhen Shen1, 2, Chen-Chen Zhu3, Li-Li Qian2, Tian-Jiao Zhang2, Min Li2, Jing Zhu2, Da-Bao Wu2, Ying Zhou2, Xing-Sheng Yang1, *()
1Department of Gynecology and Obstetrics, Qilu Hospital Affiliated to Shandong University, Jinan, 250012 Shandong, P. R. China
2Department of Obstetrics and Gynecology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, 230001 Anhui, P. R. China
3Anhui Medical University, Anhui Provincial Hospital, Hefei, 230001 Anhui, P. R. China
Download:  PDF(871KB)  ( 63 ) Full text   ( 10 )
Export:  BibTeX | EndNote (RIS)      
Abstract  
Objectives: In order to improve the early diagnosis of ovarian cancer (OC), we evaluated human epididymis secretory protein 4 (HE4), the risk of malignancy index (RMI), the risk of ovarian malignancy algorithm (ROMA), and the Copenhagen Index (CPH-I) in their ability to predict the risk of adnexal masses being malignant, and in discriminating between serous and mucinous ovarian tumors. Methods: A study consisting of 509 patients who were diagnosed with benign, borderline, and malignant adnexal tumors was conducted. We analyzed the values of HE4, RMI, ROMA, and CPH-I. In addition, CA125, CEA, CA125/CEA ratio, CA199, and CA125/CA199 ratio were also assessed to determine their predictive values to diagnoses serous or mucinous ovarian tumors. Results: To differentiate between benign and borderline ovarian tumors, we evaluated RMI and CPH-I scores which showed high AUC (0.7593, and 0.7128, respectively), but neither of them showed both high sensitivity and specificity. When discriminating benign and malignant tumors, RMI and CPH-I performed the best for premenopausal women; whereas ROMA and HE4 performed the best for postmenopausal women. Patients with values above the cutoff for CA125 (> 328.3 U/mL), CA125/CEA (> 82.26), and CA125/CA199 (> 5.633), were more likely to be diagnosed with serous carcinoma. Whereas those with higher values for CEA (> 3.7 μg/L) and CA199 (> 27.81 ng/mL) were more likely to have a mucinous carcinoma. Conclusion: RMI and CPH-I for premenopausal women, ROMA and RMI for postmenopausal women were reliable indicators to differentiate between women with benign versus malignant tumors. In addition, the ratios CA125/CEA and CA125/CA199 could be used to distinguish serous from mucinous ovarian carcinomas.
Key words:  CPH-I      HE4      Ovarian tumors      RMI      ROMA     
Submitted:  09 July 2020      Revised:  19 October 2020      Accepted:  20 October 2020      Published:  15 February 2021     
Fund: 
2018YFC1003900/National Key Research and Development Program
81872110/National Natural Science Foundation of China
81902632/National Natural Science Foundation of China
1704a0802151/Anhui Provincial Key Research and Development Program
*Corresponding Author(s):  Xing-Sheng Yang     E-mail:  yxssddx@outlook.com

Cite this article: 

Zhen Shen, Chen-Chen Zhu, Li-Li Qian, Tian-Jiao Zhang, Min Li, Jing Zhu, Da-Bao Wu, Ying Zhou, Xing-Sheng Yang. Using HE4, RMI, ROMA and CPH-I in the differential diagnosis of adnexal masses. European Journal of Gynaecological Oncology, 2021, 42(1): 139-147.

URL: 

https://ejgo.imrpress.com/EN/10.31083/j.ejgo.2021.01.2192     OR     https://ejgo.imrpress.com/EN/Y2021/V42/I1/139

[1] Subramanyeshwar Rao Thammineedi, R. Rajagopalan Iyer, Naren Boleneni. Laparoscopy-assisted excision of an ovarian fibroma in an 18-month-old toddler: a case report[J]. European Journal of Gynaecological Oncology, 2021, 42(1): 161-164.
[2] Francesco Plotti, Bartolone Martina, Terranova Corrado, Luvero Daniela, Scaletta Giuseppe, Gatti Alessandra, Benedetti Panici Pierluigi, Angioli Roberto. Role of human epididymis protein 4 (HE4) as predictor of response to platinum based chemotherapy: a systematic review of literature[J]. European Journal of Gynaecological Oncology, 2020, 41(6): 889-896.
[3] Laura Baquedano Mainar,Andrea Espiau Romera, Pluvio Jesús Coronado Martín. HE4 in endometriod and non- endometrioid subtype of endometrial cancer does not mean the same[J]. European Journal of Gynaecological Oncology, 2020, 41(6): 1039-1044.
[4] Adrius Gaurilcikas, Migle Gedgaudaite, Saulius Paskauskas, Tomas Birzietis, Daiva Vaitkiene. Unusual case of Krukenberg tumors diagnosed in early pregnancy[J]. European Journal of Gynaecological Oncology, 2020, 41(5): 806-809.
[5] Yi-fan Luo, Li-xiang Ren, Ming-yan Jiang, Yang Chu. A systematic review and meta-analysis on the effects of metformin on survival outcomes and risk in women with cervical cancer[J]. European Journal of Gynaecological Oncology, 2020, 41(4): 504-507.
[6] Krittiya Somaketarin, Charuwan Tantipalakorn, Kittipat Charoenkwan, Prapaporn Suprasert, Jatupol Srisomboon. Survival outcomes of sex cord-stromal tumors of the ovary[J]. European Journal of Gynaecological Oncology, 2020, 41(4): 563-568.
[7] Chiharu Mizoguchi, Harunobu Matsumoto, Kaei Nasu, Kentaro Kai, Motoki Arakane, Hisashi Narahara. Collision tumour of endometrial stromal sarcoma, uterine tumour resembling ovarian sex-cord tumour, and leiomyoma[J]. European Journal of Gynaecological Oncology, 2020, 41(4): 634-637.
[8] Tingting Cao, Naze Chen, Huaxin Sun, Rong Zhou, Jianliu Wang, Xiuju Yin. A rare case of primary extrauterine endometrial stromal sarcoma involving the sigmoid colon[J]. European Journal of Gynaecological Oncology, 2020, 41(4): 661-663.
[9] J. An, G. Ruan, X.Y. Xie, Y.Q. Shi, X.D. Mao, B.H. Dong, P.M. Sun. Endometrial stromal nodule: report of 8 cases and literature review[J]. European Journal of Gynaecological Oncology, 2020, 41(3): 332-338.
[10] Guolin Liu, Rui Zhang. Postmenopausal recurrent retrovaginal extramural gastrointestinal stromal tumor: a case report[J]. European Journal of Gynaecological Oncology, 2020, 41(3): 473-476.
[11] A. R. H. Ahmed, R. A. Bakheet, W. Abdelmohsen, M. Mohammed, M. A. Adly. Balance of glandular and stromal Bcl2/Bax expression in pre-neoplastic and neoplastic endometrial tissues[J]. European Journal of Gynaecological Oncology, 2020, 41(2): 265-272.
[12] J. Yang, Y.J. Song, Y.J. Na, H.G. Kim. A Case of Fertility Sparing Surgery of Low-Grade Endometrial Stromal Sarcoma in Young Female[J]. European Journal of Gynaecological Oncology, 2020, 41(2): 317-319.
[13] J. Liang, X. Yang, L. Liu, L. Qiao, P. Peng, J. Zhou. Combined measurement of miRNA-183, HE4, and CA-125 increases diagnostic efficiency for ovarian cancer[J]. European Journal of Gynaecological Oncology, 2020, 41(1): 30-35.
[14] Z. Xu, H. Wen, Q. Xue. Successful pregnancy achieved by in vitro fertilization after fertility-preserving treatments in an infertile woman with borderline ovarian tumor and endometrial complex atypical hyperplasia: a case report[J]. European Journal of Gynaecological Oncology, 2020, 41(1): 126-129.
[15] S.G. Kim, Y.S. Kim, H.J. Lee. A giant fibroma associated with Meigs' syndrome misdiagnosed as a giant myoma: a case report[J]. European Journal of Gynaecological Oncology, 2020, 41(1): 134-137.
No Suggested Reading articles found!